EMA Authorised: Jemperli (dostarlimab) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised dostarlimab (Jemperli) for endometrial cancer, expanding treatment options for endometrial neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)

Snippet

Status: Authorised. Therapeutic area: Endometrial Neoplasms. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 31/03/2026